Capmatinib

Major

Capmatinib Propranolol Hemangeol Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Ramelteon Rozerem Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Ranolazine Aspruzyo Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Capmatinib Repotrectinib Augtyro Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Capmatinib Rifabutin Mycobutin Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Rifampin Rifadin Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Riluzole Exservan Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Rivaroxaban Xarelto Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Ropivacaine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Rosuvastatin Crestor Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Capmatinib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Sirolimus Felycin Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Sofosbuvir Sovaldi Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib St John's Wort Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Sulfasalazine Azulfidine Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Tacrine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Talazoparib Talzenna Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Tasimelteon Hetlioz Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Capmatinib Tenofovir Alafenamide Risk of increased adverse reactions Details Capmatinib Theophylline Accurbron® Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Tizanidine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Tolvaptan Jynarque Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Topotecan Hycamtin Risk of increased adverse reactions Details Capmatinib Ubrogepant Ubrelvy Risk of increased adverse reactions Details Capmatinib Velpatasvir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Venetoclax Venclexta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Vorasidenib Voranigo Increased vorasidenib exposure and an increased risk of vorasidenib-related adverse reactions Details Capmatinib Voriconazole Vfend Increased tyrosine kinase inhibitors exposure Details Capmatinib Voxilaprevir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Warfarin Coumadin Increased warfarin exposure and an increased INR Details Capmatinib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Capmatinib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Capmatinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Capmatinib Irinotecan Injection Camptosar Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Capmatinib Methotrexate Injection Abitrexate® Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Capmatinib Nafcillin Injection Unipen® Injection Decreased capmatinib exposure and reduction of antitumor activity Details